الفهرس | Only 14 pages are availabe for public view |
Abstract Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people globally in the last few decades. Type 2 Diabetes Mellitus (DM), which used to be called ”non-insulin dependent DM,” is the most common type of DM. It accounts for approximately 90% of diabetes cases. It is marked by high blood glucose levels, insulin resistance, and a relative lack of insulin. The combination of genetic, environmental, and behavioural risk factors leads to type 2 diabetes. Hyperglycemia in type 2 diabetes patients can be managed with a variety of successful therapies that either increase insulin production or decrease insulin resistance in peripheral tissues. However, Conventional antidiabetic dosage forms have a lot of problems that necessitate searching for novel drug delivery systems to overcome these drawbacks. Niosomes and proniosomes have been used to carry a wide variety of antidiabetic drugs achieving controlled and sustained release which improves patient compliance. This work describes the fundamental aspects of niosomes and Proniosomes including their structural components, methods of preparation, advantages and drawbacks, characterization, factors affecting niosomes formation along with their application in treatment of diabetes. It also highlights the participation of other drug delivery systems in treatment of diabetes done mainly in the last decade. Repaglinide (RPG) has a low water solubility of about 20 μg/mL and undergoes extensive first pass metabolism, resulting in relatively limited bioavailability (50%) and the need for multiple dosing to manage blood glucose levels. Because to RPG’s short half-life, it must be administered frequently to establish therapeutic efficacy. Frequent administration of traditional pills leads to poor adherence by the patient to the treatment plan, reducing the effectiveness of RPG in controlling blood glucose levels. So, there is a need for a new formula to enhance it’s bioavailability. RPG was successfully entrapped within the produced niosomes formulations’ lipid bilayers. Design expert suugests that the optimized formula is the one with span 60 : cholesterol : peceol ratio of 1:1:1.528. characterization of this formula showed particle size (PS) II of 306.600 ± 84.00 nm, Zeta potential (ZP) of -38.600 ± 1.20, polydispersity index (PDI) of 0.480 ± 0.05 and entrapment efficiency percent (EE%) of 92.000 ± 2.60. The Optimized Niosomal Formulation (ONF) was successfully loaded into tablets utilising three different co-processed excipients via direct compression. The in vitro release profiles revealed that the improved ONF had superior absorption and a longer RPG effect. In vivo investigations revealed that Pharmaburst® 500 and F-melt® tablets had much higher and longer hypoglycemic activity than the market product, Novonorm® tablets. As a result, tablets made with co-processed excipients containing ONF could be potential oral drug delivery methods for diabetes II with improved oral absorption. They have both an immediate hypoglycemic effect and long-term anti-diabetic effects. |